TrendingWallStreet.com Releases Volume Alerts on GRPN, ENIP, PBYI, and APDN


Follow this company

Companies Mentioned

NASDAQ:GRPN / OTC:BB:ENIP / NYSE:PBYI / PK:APDN
12/18/2013 [ACCESSWIRE]

Whether it’s a bull or bear market, TrendingWallStreet has you covered. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get exclusive access to our free stock reports.

Groupon, Inc. (NASDAQ: GRPN) shares closed up 2.99 percent on Tuesday with about 18.4 million shares traded. The stock was one of the most active stocks in the NASDAQ. Groupon, one of the fastest growing companies in ecommerce, has selected Borderlinx Global eCommerce Solutions to help facilitate Canadian cross-border U.S. sales for the company's Groupon Goods channel. Through Borderlinx's compliant, secure and reliable cross-border trade solutions, Groupon is able to provide its Canadian customers with the capability to purchase a broader selection of Groupon Goods deals available in the United States and ship them to Canada.

Get more information on Groupon, Inc. and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/GRPN

Endeavor IP, Inc. (OTCBB: ENIP) shares closed up 17.99 percent on Tuesday with around 2.3 million shares traded. The stock was one of the biggest gainers in the OTCBB market and hit a new 52-week high of $0.75 during intra-day trading. The company had no significant news.

Get more information on Endeavor IP, Inc. and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/ENIP

Puma Biotechnology, Inc. (NYSE: PBYI) shares closed up 11.98 percent on Tuesday with about 1.3 million shares traded. The stock was one of the biggest gainers in the NYSE and hit a new 52-week high of $105.00 during intra-day trading. The company announced that it will host a conference call at 1:30 p.m. PST (4:30 p.m. EST) on Monday, December 23, 2013, to provide an update on its clinical trials of PB272 (neratinib) in cancer patients with activating HER2 mutations. This includes the Company’s ongoing trials of neratinib in (1) patients with HER2 mutated non-small cell lung cancer; (2) patients with HER2-negative breast cancer who have a HER2 mutation; and (3) patients with solid tumors who have an activating HER2 mutation.

Get more information on Puma Biotechnology, Inc. and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/PBYI

Applied DNA Sciences Inc. (OTC: APDN) shares closed down 10.67 percent on Tuesday with over 6 million shares traded. The company had one of the biggest percentage drops in the OTC market. The company announced the success of a large-scale trial of its new SigNature T anti-counterfeiting platform to assure identity and originality of textiles and apparel. The trial, in collaboration with one of the world's foremost textile organizations, displayed the capacity of the APDN platform for use in protecting massive international cotton crops from counterfeiting and dilution.

Get more information on Applied DNA Sciences Inc. and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/APDN

 

Disclosure: TrendingWallStreet.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.

COMMENTS

Leave a comment...
 * 

Your Name
 *